TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01405300

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 34.8 g dextrose, 150 g heavy whipping cream, 39g chocolate syrup, 15 g sunflower oil, 22 g safflower oil, 27 g powdered egg whites, 9.6 g of fiber supplement, water and crushed ice. It will deliver \~1200 kcal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peanut
Description: 34.8 g dextrose. 137 g heavy whipping cream, 39g chocolate syrup + 3 oz peanuts with skin. It will deliver \~1200 kcal.
Study: NCT03650088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss with digital tools
Description: Participants will monitor their diet in a study smart phone app using a 'traffic light' approach where foods are categorized as red (high fat and/or calorie), yellow (moderate fat/calorie, high nutrient), or green (low fat/calorie, high nutrient) and adhere to a red food limit recommendation, weigh daily on a digital scale whose data syncs to the study app, gradually increase physical activity and track it using a wearable device for which data is also synced to the app, and monitor blood glucose using Continuous Glucose Monitoring. Participants will meet weekly with a trained interventionist for behavioral lessons (adapted from Diabetes Prevention Program curriculum) and counseling.
Study: NCT01022658

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: For diabetes treatment: metformin continued with insulin (according to arms)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: For diabetes treatment: metformin continued with insulin (according to arms)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: For diabetes treatment: metformin continued with insulin (according to arms)
Study: NCT03945461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing gum
Description: xylitol based, peppermint flavored gum
Study: NCT00100789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 3,000 mg/m2 IV over 30 minutes on days 1 and 15 (q28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 150 mg/m2 IV over 1 hour on days 1 and 15 (q 28 day cycle), administered after gemcitabine
Study: NCT01725217

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: 1 vaccination at visit 1, conjugate vaccine, Intramuscular (IM) injection
Study: NCT03472950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine 500 MG
Description: Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine 1000 MG
Description: Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).
Study: NCT00064987

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Testicular biopsy
Description: Outpatient surgical procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Testicular biopsy
Description: Outpatient surgical procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gonadotropin releasing hormone (GnRH)
Description: Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gonadotropin releasing hormone (GnRH)
Description: Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: follicle stimulating hormone (FSH)
Description: 75 IU subcutaneous injection daily for four months.
Study: NCT03495375

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment with a probiotic
Description: All participants will take the probiotic once daily for 10 weeks in the form of a powder that can be spread on top of cold foods such as muesli, salad, or yogurt.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment with placebo
Description: All participants will take the placebo once daily for 10 weeks.
Study: NCT03948646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofpironium Bromide, 15%
Description: Active
Study: NCT04185675

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The laryngoscope used for tracheal intubation under general anesthesia for patients with expected non-difficult airway conditions.
Description: All the patients will receive the same anesthesia induction, and are randomized to three groups to receive different types of laryngoscope for intubation. These are the direct Macintosh laryngoscope, adjustable videolaryngoscope and nonadjustable videolaryngoscope.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The laryngoscope used for tracheal intubation under general anesthesia for patients with expected non-difficult airway conditions.
Description: All the patients will receive the same anesthesia induction, and are randomized to three groups to receive different types of laryngoscope for intubation. These are the direct Macintosh laryngoscope, adjustable videolaryngoscope and nonadjustable videolaryngoscope.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The laryngoscope used for tracheal intubation under general anesthesia for patients with expected non-difficult airway conditions.
Description: All the patients will receive the same anesthesia induction, and are randomized to three groups to receive different types of laryngoscope for intubation. These are the direct Macintosh laryngoscope, adjustable videolaryngoscope and nonadjustable videolaryngoscope.
Study: NCT00307905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traumeel S
Description: homeopathic remedy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo remedy
Description: identical size, shape and taste of treatment medication
Study: NCT02506192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified-Release Prednisone
Description: Modified-Release Prednisone oral tablets (2x5mg) daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablets (2x5mg) daily for 8 weeks
Study: NCT03070535

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIGH and LOW meal ingestion
Description: The study will examine CSF biomarker responses to HIGH and LOW meals in 80 men and women with and without the E4 allele in a cross-over design. After an overnight fast, participants will ingest either a HIGH or LOW meal on separate days 3-5 weeks apart in random order. Three hours after meal ingestion, participants will undergo a cognitive battery, followed by spinal fluid collection. Blood samples will also be taken at 7 time points before and after meal ingestion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIGH and LOW meal ingestion
Description: The study will examine CSF biomarker responses to HIGH and LOW meals in 80 men and women with and without the E4 allele in a cross-over design. After an overnight fast, participants will ingest either a HIGH or LOW meal on separate days 3-5 weeks apart in random order. Three hours after meal ingestion, participants will undergo a cognitive battery, followed by spinal fluid collection. Blood samples will also be taken at 7 time points before and after meal ingestion.
Study: NCT03029910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy and eccentric exercise
Description: 12 weeks, 5 days/week, once a day, 2 exercises, 3 sets/exercise, 15 repetition/set. Of excentric exercise of foot plantar flexors. First exercise with knee in extension. Second exercise with knee in flexion. Previously subjects should cool their leg in ice water during sixteen minutes at a temperature of 8ºC (+/-2ºC)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration and eccentric exercise
Description: 12 weeks, 5 days/week, once a day, 2 exercises, 3 sets/exercise, 15 repetition/set. Of excentric exercise of foot plantar flexors. First exercise with knee in extension. Second exercise with knee in flexion. During the exercise subjects will be subjected to vibration. Vibration parameters: Frequency: 35Hz, Amplitude: 4 millimeters, Force: 3,9G
Study: NCT02938208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jupiter Full Face Mask
Description: Full Face Mask for the treatment of obstructive sleep apnea (OSA) using CPAP therapy.
Study: NCT01588561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Nicotine
Description: Subjects received a single infusion of nicotine, 1.5 mg/70kg (New England Compounding Center, Framingham, MA), administered over 1 minute into the antecubital vein 10 minutes into their MRI scans.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline - placebo
Description: Subjects received a single infusion of saline, administered over 1 minute into the antecubital vein 10 minutes into their MRI scans.
Study: NCT03337971

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: A food-grade proprietary product containing corn starch in powder form, flavoured and instantised to be dissolved in water. Supplied by Dairygold Ingredients, Mitchelstown, Co Cork, Ireland

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MBPM
Description: A food-grade proprietary product containing per 100g; milk protein (46.4%), carbohydrate (40.6%), fat (0.7%), Vitamin D (2ug); calcium (1840mg) in powder form, flavoured and instantised to be dissolved in water. Supplied by Dairygold Ingredients, Mitchelstown, Co Cork, Ireland
Study: NCT02068625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: Rasagiline 1mg daily orally for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral treatment with placebo for 7 days
Study: NCT01435213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atipamezole
Description: Administration of a single dose of 5-150 micrograms of atipamezole as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: A single dose of 1.2 mg/kg of atomoxetine administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A single dose of ketamine (approximately 60 mg) administered as an intravenous infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Description: 30-45 min cold pressor test of the foot

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin administered as an intravenous infusion to induce hypoglycemia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single dose of placebo (capsules) administered orally
Study: NCT03513276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100cc of 2% ropivacaine
Description: Multimodal analgesia + Local infiltration anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution
Description: Multimodal analgesia + Saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenaline 10mcg/ml
Study: NCT01327677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 25-50 mcg every 20 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 20mcg/demand dose with an 8 minute lock out
Study: NCT01693536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counselling
Description: as in Arm Description
Study: NCT03038295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Oral propranolol:0.25mg/kg daily(every 24 hours)；Eye drop propranolol(0.2%):3 microdrops,in each eye, four times daily (every 6 hours) .Both administration routes will be discontinued until retinal vascularization will be completed, but no more than 90 days.The study will be discontinued immediately in the presence of serious adverse effects attributable to the pharmacological actions of propranolol (severe hypotension, bradycardia or bronchospasm).In case of surgery or induction of anesthesia during the administration of propranolol, the drug should be discontinued at least 24 hours before surgery.In cases of severe hypotension or bradycardia may be administered one or more of the following drugs:Atropine.Isoproterenol hydrochloride (isoprenaline).Terlipressin.Glucagon In case of severe bronchospasm may be used salbutamol aerosol or salbutamol + ipratropium bromide. Betamethasone could be used for aerosol or systemic (intravenous or intramuscular).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Oral propranolol:0.25mg/kg daily(every 24 hours)；Eye drop propranolol(0.2%):3 microdrops,in each eye, four times daily (every 6 hours) .Both administration routes will be discontinued until retinal vascularization will be completed, but no more than 90 days.The study will be discontinued immediately in the presence of serious adverse effects attributable to the pharmacological actions of propranolol (severe hypotension, bradycardia or bronchospasm).In case of surgery or induction of anesthesia during the administration of propranolol, the drug should be discontinued at least 24 hours before surgery.In cases of severe hypotension or bradycardia may be administered one or more of the following drugs:Atropine.Isoproterenol hydrochloride (isoprenaline).Terlipressin.Glucagon In case of severe bronchospasm may be used salbutamol aerosol or salbutamol + ipratropium bromide. Betamethasone could be used for aerosol or systemic (intravenous or intramuscular).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral/eye drop placebo will be taken in enrolled newborns. Other treatment will follow the standard treatment schedule of Early Treatment For Retinopathy Of Prematurity Cooperative Group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral/eye drop placebo will be taken in enrolled newborns. Other treatment will follow the standard treatment schedule of Early Treatment For Retinopathy Of Prematurity Cooperative Group.
Study: NCT04208555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boric Acid Vaginal Suppository
Description: Boric acid vaginal suppository (600 mg/day) for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terconazole Vaginal Suppository
Description: Terconazole 80 mg vaginal suppository daily for 6 days
Study: NCT03948646

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle gel
Study: NCT01736982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants earn reinforcement in the form of prizes for breath samples that test negative for cigarette smoking.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard smoking cessation counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard smoking cessation counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: transdermal nicotine replacement \[21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)\]

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: transdermal nicotine replacement \[21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)\]

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Breath sample monitoring
Study: NCT01957514

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo tissue biopsy, blood, buccal mucosa, saliva, and urine collection

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03052751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB7665
Description: UCB7665 will be administered in 2 different dosages (dose 1 and dose 2). UCB7665 (INN: Rozanolixizumab) is a humanized monoclonal antibody that is being developed for treatment of IgG autoantibody-mediated conditions such as myasthenia gravis (MG)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB7665
Description: UCB7665 will be administered in 2 different dosages (dose 1 and dose 2). UCB7665 (INN: Rozanolixizumab) is a humanized monoclonal antibody that is being developed for treatment of IgG autoantibody-mediated conditions such as myasthenia gravis (MG)
Study: NCT00983281

Intervention type: DRUG
Intervention: Hextend
Description: IV fluid resuscitation to restore euvolemia after traumatic injury and surgery.

Intervention type: DRUG
Intervention: Hextend
Description: IV fluid resuscitation to restore euvolemia after traumatic injury and surgery.
Study: NCT02041130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Study: NCT00301405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Open label drug
Study: NCT00183716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Recovery and Empowerment Model (TREM)
Description: TREM is a 29-session group intervention for women who have experienced psychological trauma (e.g., childhood physical or sexual abuse), focusing on skill development, understanding the effects of trauma, and empowerment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Participants will receive usual care for women who have experienced psychological trauma.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will receive usual care for women who have experienced psychological trauma.
Study: NCT02239250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Water filter and cookstove
Description: The Vestergaard Frandsen Lifestraw Family™ 2.1 is a point-of-use water treatment system.Water is poured through a 20 micron pre-filter into a 6L influent water tank.This water then filters through a 0.20 micron hollow-fiber ultrafiltration membrane into a 5.5L storage container.Water is then poured through a plastic tap, which prevents re-contamination.This system filters up to 18,000L of water.The system exceeds the WHO's highly protective standard for household water treatment technologies.The EcoZoom™ Spartan stove concentrates the combustion process while channeling airflow to completely burn the fuel provided.The stove has a ceramic combustion chamber within a steel housing, which is topped with a cast iron stove.The stove includes a rack for placing firewood and a pot skirt that improves the thermal efficiency.The cookstoves and filters will be delivered together at no cost to participating households.Households will receive instructions on how to operate these devices.
Study: NCT04152447

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VR device
Description: Patients use a VR device
Study: NCT01736982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Breath sample monitoring
Study: NCT04111666

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AL101
Description: Active dose of AL101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AL101
Description: Active dose of AL101

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution administered as a single and multiple infusion as placebo.
Study: NCT01995604

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Application of Sterile 0.9% Saline Solution
Description: Application of Sterile 0.9% Saline Solution to half of face after UltraPulse laser therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of dHACM
Description: Application of dHACM to half of face after UltraPulse laser therapy.
Study: NCT00683462

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3480
Description: Capsules 5 mg/day (once a day) for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3480
Description: Capsules 50 mg/day (once a day) for 2 weeks
Study: NCT00924313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (C-11 Acetate)
Description: 11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection
Study: NCT02583594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alemtuzumab GZ402673
Description: Pharmaceutical form:solution for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alemtuzumab GZ402673
Description: Pharmaceutical form:injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceterizine
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceterizine
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine
Description: Pharmaceutical form:tablet Route of administration: oral